Latest news
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - simplywall.stsimplywall.st · Sat, 08 Aug 2026 03:05:24 GMTAnalyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained - TipRanksTipRanks · Fri, 07 Aug 2026 23:12:02 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTDenali Therapeutics: Blood-Brain Barrier Platform Shows More Than 1,000x Greater Brain Exposure In Primates As AVLAYAH Launch Accelerates - Pulse 2.0Pulse 2.0 · Fri, 07 Aug 2026 15:50:29 GMTDenali Q2 2026 Earnings: AVLAYAH Launch Generates $3.6 Million - TradingKeyTradingKey · Fri, 07 Aug 2026 01:45:02 GMTDNLI: AVLAYAH's launch drove $3.6M revenue and strong adoption, with Q3 guidance of $10–12M - TradingViewTradingView · Thu, 06 Aug 2026 23:10:45 GMTDenali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:14:03 GMTDenali Therapeutics reports $3.6M in Q2 2026 product revenue, pro forma cash >$1.1B - TradingViewTradingView · Thu, 06 Aug 2026 20:13:22 GMT